Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panitumumab biosimilar - Qilu Pharmaceutical

Next Previous
Drug Profile

Panitumumab biosimilar - Qilu Pharmaceutical

Alternative Names: QL 1203

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 16 Feb 2026 Panitumumab biosimilar is still in phase III trials for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in China (IV)
  • 23 Jan 2025 Efficacy and adverse events data from phase III trial in Colorectal cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GI-2025)
  • 09 Jun 2023 QL 1203 is still in phase-I development in Cancer (In volunteers) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top